<DOC>
	<DOCNO>NCT00778037</DOCNO>
	<brief_summary>To compare single-dose oral bioavailability Cyclobenzaprine hydrochloride 10 mg tablet Ohm Labs Inc ( A subsidiary Ranbaxy Pharmaceuticals Inc USA . ) Flexeril® 10 mg tablet ( contain Cyclobenzaprine hydrochloride 10 mg ) McNeil Consumer &amp; Specialty Pharmaceuticals , healthy , adult , male , human subject fast condition .</brief_summary>
	<brief_title>Bioequivalence Study Cyclobenzaprine Hydrochloride 10 mg Tablets , USP Under Fasting Conditions</brief_title>
	<detailed_description>The study conduct open label , balance , randomize , two-treatment , two-sequence , two-period , single-dose , crossover , bioavailability study compare Cyclobenzaprine hydrochloride 10 mg tablet Ohm Labs Inc ( A subsidiary Ranbaxy Pharmaceuticals Inc USA . ) Flexeril® 10 mg tablet ( contain Cyclobenzaprine hydrochloride 10 mg ) manufacture Merck &amp; Co Inc. , USA distribute McNeil Consumer &amp; Speciality Pharmaceuticals , healthy , adult , male , human subject fast condition . Following overnight fast least 10 hour , A single oral dose one Cyclobenzaprine hydrochloride 10 mg tablet administer 240 mL drinking water ambient temperature period study supervision train Study Personnel . During course study safety parameter assess vital sign , clinical examination , medical history clinical laboratory safety test ( hematology , biochemical parameter , serology urine analysis ) baseline . Laboratory parameter hematology biochemistry repeat end study . A total forty ( 40 ) subject enrol study . Out thirty-four ( 34 ) subject complete period study .</detailed_description>
	<mesh_term>Cyclobenzaprine</mesh_term>
	<mesh_term>Amitriptyline</mesh_term>
	<criteria>Were age range 1845 year . Were neither overweight underweight height per Life Insurance Corporation India height/weight chart nonmedical case . Had voluntarily give write informed consent participate study Were normal health determine medical history physical examination subject perform within 21 day prior commencement study . Hypersensitivity allergy Cyclobenzaprine hydrochloride relate group drug . Use MAO Inhibitors past 2 week / history Hyperthyroidism . History hypotension , dizziness , syncope previously experience hypotensive response medication . History arrhythmia , heart block congestive heart failure . History urinary disorder especially urinary retention . History seizure , tinnitus , tremor , visual disorder , psychosomatic illness , recurrent palpitation , Jaundice . Any evidence organ dysfunction clinically significant deviation normal , physical clinical determination . Presence disease marker HIV 1 2 , Hepatitis B C viruses syphilis infection . Presence value significantly different normal reference range and/or judge clinically significant haemoglobin , total white blood cell count , differential WBC count platelet count . Positive urinary screen test drug abuse ( opiates cannabinoids ) Presence value significantly different normal reference range and/or judge clinically significant serum creatinine , blood urea nitrogen , serum aspartate aminotransferase ( AST ) , serum alanine aminotransferase ( ALT ) , serum alkaline phosphatase , serum bilirubin , plasma glucose serum cholesterol . Clinically abnormal chemical microscopic examination urine define presence RBC , WBC ( &gt; 4/HPF ) , epithelial cell ( &gt; 4/HPF ) , glucose ( positive ) protein ( positive ) . Clinically abnormal ECG Chest Xray . History serious gastrointestinal , hepatic , renal , cardiovascular , pulmonary , neurological hematological disease , diabetes , glaucoma increase intra ocular pressure . History psychiatric illness might impair ability provide write informed consent . Regular smoker smoke 10 cigarette daily difficulty abstain smoke duration study period . History drug dependence excessive alcohol intake habitual basis 2 unit alcoholic beverage per day ( 1 unit equivalent half pint beer 1 glass wine 1 measure spirit ) difficulty abstain duration study period . Used enzyme modify drug within 30 day prior Day 1 study . Participated clinical trial within 12 week precede Day 1 study . Subjects , completion study , would donate and/or lose 350 mL blood past 3 month .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Bioequivalence Cyclobenzaprine hydrochloride 10 mg tablet fasting condition</keyword>
</DOC>